Biopharmaceutical
Therapy
Health

Celgene

$88.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.48 (-1.65%) Today
+$0.09 (0.10%) After Hours

Why Robinhood?

You can buy or sell Celgene and other stocks, options, ETFs, and crypto commission-free!

About

Celgene Corporation Common Stock, also called Celgene, is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. Read More The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Employees
8,852
Headquarters
Summit, New Jersey
Founded
1986
Market Cap
61.72B
Price-Earnings Ratio
15.94
Dividend Yield
0.00
Average Volume
7.40M
High Today
$89.49
Low Today
$87.96
Open Price
$89.22
Volume
2.66M
52 Week High
$95.30
52 Week Low
$58.59

Collections

Biopharmaceutical
Therapy
Health
Medical
Cancer Prevention
Biotechnology
Pharmaceutical
Technology

News

Seeking AlphaMar 22

Starboard's Smith stays the course in opposing Bristol-Myers/Celgene tie-up

In an interview on CNBC, Starboard Value's Jeff Smith reiterated his opposition to Bristol-Myers Squibb's (BMY -0.8% ) announced $74B takeover of Celgene (CELG -1.2% ), citing its over-generous bid considering CELG's looming patent cliff and doubts that it will be able to produce 10 new blockbusters in the next eight years.

113
Yahoo FinanceMar 21

Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April. Bristol-Myers Squibb Company BMY is facing strong criticism from activist investors for the proposed acquisition of another large pharmaceutical company, Celgene Corporation CELG. Bristol-Myers investors have expressed multiple concerns related to growth of the company following the merger. We remind investors that Bristo...

229
Barron'sMar 21

Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.

Text size Management and shareholders at Bristol-Myers Squibb continue to spar over the firm’s proposed acquisition of Celgene . Recommendations from proxy-advisory firms—expected next week—could tilt the scales, according to Credit Suisse analyst Vamil Divan. The back story. Bristol-Myers (ticker: BMY) said in January that it was purchasing biotech drugmaker Celgene (CELG) for $74 billion. Not everyone thinks that is a good move. One of the pharmaceutical company’s largest shareholders, Wellington Manag...

138

Earnings

$1.78
$1.98
$2.19
$2.39
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 3, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.